CEL SCI CORP
CVMCel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How CVM's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LI | Phase 3 | Squamous Cell Carcinoma of the Oral Cavity | - | - |
Frequently asked questions
What is in CEL SCI CORP's drug pipeline?→
CatalystAlert tracks 1 drug candidate in CEL SCI CORP's (CVM) pipeline across Phase 3. Its lead program is LI (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CEL SCI CORP's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CEL SCI CORP (CVM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CVM biotech catalysts?→
Add CVM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CEL SCI CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.